Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Zycos Inc (AKA: Pangaea Pharmaceuticals Inc)
Profile last edited on: 5/16/19      CAGE:       UEI:

Business Identifier: DNA-based drugs for the treatment of cancer
Year Founded
----
First Award
1998
Latest Award
1998
Program Status
Inactive (Acquired)
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

44 Hartwell Avenue
Lexington, MA 02421
   (781) 274-6500
   N/A
   www.zycos.com
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

In September 2004, MGI PHARMA (Nasdaq: MGON), a MN based oncology-focused biopharmaceutical company that acquired, developed and commercialized proprietary products, acquired Zycos, Formerly known as Pangaea Pharmaceuticals Inc, Zycos Inc had been a privately held biotechnology company focused on developing oncology and antiviral products. The name ZYCOS is - appropriately derived from a word of Greek origin, which means "life"

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$129,055
Phase II Dollars
$0
Total Awarded
$129,055

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
1998 1 NIH $129,055
Project Title: Polymer Delivered DNA Therapeutic For Cervical Dysplasia

Key People / Management

  Mark A Philip -- President

  Mary Hedley

Company News

There are no news available.